EP 0714399 A4 19990127 - HSV-2 UL26 GENE, CAPSID PROTEINS, IMMUNOASSAYS AND PROTEASE INHIBITORS

Title (en)

HSV-2 UL26 GENE, CAPSID PROTEINS, IMMUNOASSAYS AND PROTEASE INHIBITORS

Title (de)

HSV-2 UL26 GEN, HÜLLPROTEINE, IMMUNOASSAYS UND PROTEASEINHIBITOREN

Title (fr)

GENE HSV-2 UL26, PROTEINES CAPSIDES, DOSAGES IMMUNOLOGIQUES ET INHIBITEURS DE PROTEASE

Publication

EP 0714399 A4 19990127 (EN)

Application

EP 94925924 A 19940819

Priority

US 9409303 W 19940819
US 11052293 A 19930820
US 26453794 A 19940623

Abstract (en)

[origin: WO9506055A1] Essentially pure HSV-2 UL26 gene products and fragments thereof including mature HSV-2 protease and active fragments thereof are disclosed. Essentially pure HSV-2 UL26.5 gene products and fragments thereof including mature HSV-2 capsid protein and functional fragments are disclosed. Isolated nucleic acid molecules comprising all or part of the HSV-2 UL26 gene and/or the HSV-2 UL26.5 gene are disclosed. Expression vectors and host cells comprising such nucleic acid molecules are disclosed. Methods of identifying compounds that inhibit HSV-2 protease activity and methods of identifying compounds that inhibit HSV-2 virion assembly are disclosed. Synthetic HSV-2 substrates are disclosed. Antibodies that selectively bind to HSV-2 protease processed substrates but not unprocessed substrates or unprocessed substrates but not processed substrates are disclosed. Methods of and kits for distinguishing between HSV-1 DNA or protein and HSV-2 DNA or protein and reagents useful in such methods and kits are disclosed.

IPC 1-7

C07H 17/00; C12N 15/00; C12N 5/00; C12Q 1/70; A61K 38/00; A61K 35/14

IPC 8 full level

A61K 38/43 (2006.01); A61K 39/395 (2006.01); A61P 31/12 (2006.01); A61P 31/22 (2006.01); C07H 21/04 (2006.01); C07K 14/035 (2006.01); C07K 16/08 (2006.01); C12N 9/50 (2006.01); C12N 9/64 (2006.01); C12N 15/09 (2006.01); C12P 21/02 (2006.01); C12Q 1/68 (2006.01); C12Q 1/70 (2006.01); G01N 33/50 (2006.01); G01N 33/53 (2006.01); G01N 33/569 (2006.01); C12R 1/91 (2006.01)

CPC (source: EP)

A61P 31/12 (2017.12); A61P 31/22 (2017.12); C12N 9/503 (2013.01); C12Q 1/705 (2013.01); G01N 33/5008 (2013.01); G01N 33/502 (2013.01); G01N 33/5091 (2013.01); G01N 33/56994 (2013.01); G01N 2333/035 (2013.01)

Citation (search report)

[E] WO 9429456 A2 19941222 - ABBOTT LAB [US]
[X] EP 0514830 A2 19921125 - ARCH DEV CORP [US]
[X] WO 9301291 A1 19930121 - UNIV JOHNS HOPKINS [US]
[X] EP 0526652 A1 19930210 - IATRON LAB [JP]
[X] US 4430437 A 19840207 - HAMPAR BERGE [US], et al
See references of WO 9506055A1

Designated contracting state (EPC)

AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)

WO 9506055 A1 19950302; AU 7568294 A 19950321; CA 2169748 A1 19950302; CN 1133594 A 19961016; EP 0714399 A1 19960605; EP 0714399 A4 19990127; JP H09503385 A 19970408; MX PA94006367 A 20040909

DOCDB simple family (application)

US 9409303 W 19940819; AU 7568294 A 19940819; CA 2169748 A 19940819; CN 94193881 A 19940819; EP 94925924 A 19940819; JP 50765495 A 19940819; MX 9406367 A 19940819